TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 1 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,484,657 | -41.8% | 166,069 | 0.0% | 0.14% | -32.0% |
| Q2 2023 | $2,550,820 | -31.7% | 166,069 | 0.0% | 0.21% | -33.3% |
| Q1 2023 | $3,734,892 | +6.9% | 166,069 | 0.0% | 0.31% | +3.7% |
| Q4 2022 | $3,492,431 | -14.7% | 166,069 | 0.0% | 0.30% | -8.0% |
| Q3 2022 | $4,092,000 | +1.7% | 166,069 | 0.0% | 0.32% | -7.7% |
| Q2 2022 | $4,024,000 | -6.0% | 166,069 | 0.0% | 0.35% | +6.0% |
| Q1 2022 | $4,280,000 | -17.0% | 166,069 | 0.0% | 0.33% | +0.6% |
| Q4 2021 | $5,155,000 | +28.0% | 166,069 | 0.0% | 0.33% | +35.4% |
| Q3 2021 | $4,027,000 | +66.2% | 166,069 | 0.0% | 0.24% | +81.3% |
| Q2 2021 | $2,423,000 | -41.6% | 166,069 | 0.0% | 0.13% | -43.2% |
| Q1 2021 | $4,147,000 | -3.6% | 166,069 | +5.2% | 0.24% | +4.4% |
| Q4 2020 | $4,304,000 | – | 157,900 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |